Effect of triple therapy with low-dose total body irradiation and hypo-fractionated radiation plus anti-programmed cell death protein 1 blockade on abscopal antitumor immune responses in breast cancer.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 27 12 2022
revised: 05 03 2023
accepted: 09 03 2023
medline: 4 4 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

Immunostimulatory effects of radiotherapy can be synergistically augmented with immune checkpoint blockade to act both on irradiated tumor lesions and distant, non-irradiated tumor sites. Our hypothesis was that low-dose total body irradiation (L-TBI) combined with hypo-fractionated radiotherapy (H-RT) and anti-programmed cell death protein 1 (aPD-1) checkpoint blockade would enhance the systemic immune response. We tested the efficacy of this triple therapy (L-TBI + H-RT + aPD-1) in BALB/c mice with bilateral breast cancer xenografts. The L-TBI dose was 0.1 Gy. The primary tumor was treated with H-RT (8 Gy × 3). The PD-1 monoclonal antibody was injected intraperitoneally, and the secondary tumors not receiving H-RT were monitored for response. The triple therapy significantly delayed both primary and secondary tumor growths, improved survival rates, and reduced the number of lung metastasis lesions. It increased the activated dendritic and CD8

Identifiants

pubmed: 36934673
pii: S1567-5769(23)00347-8
doi: 10.1016/j.intimp.2023.110026
pii:
doi:

Substances chimiques

Programmed Cell Death 1 Receptor 0
Antibodies, Monoclonal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110026

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shuya Liu (S)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Yin Liao (Y)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Yao Chen (Y)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Hanshan Yang (H)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Yuru Hu (Y)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Zhuo Chen (Z)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Shaozhi Fu (S)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Electronic address: shaozhifu513@163.com.

Jingbo Wu (J)

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, China; Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, China. Electronic address: wjb6147@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH